BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-576@pharmaconomics
DTSTAMP:20260707T021626Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AZTR Phase 3 — ATR-12 (estimated date)
DESCRIPTION:Phase 3 trial results for ATR-12 in Netherton syndrome are due ~ Dec 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1701478/000170147826000029/aztrpressrelease3312026-ex.htm\n\nTrack it: https://pharmaconomics.com/e/576
URL:https://pharmaconomics.com/e/576
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:AZTR catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR